Avalyn Pharma (AVLN) enlarges Boston lease, adding 4,934 sq ft
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Avalyn Pharma Inc. entered into a First Amendment to its sublease with CRISPR Therapeutics, expanding its Boston headquarters space at 105 West First Street.
The leased premises increase from approximately 8,774 to 13,708 rentable square feet as of June 29, 2026. Future minimum lease payments will rise by about $924,000 over the remaining lease term, while all other sublease terms remain in effect.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 1.01, 9.01
2 items
Item 1.01
Entry into a Material Definitive Agreement
Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Original leased space: 8,774 rentable sq ft
Expanded leased space: 13,708 rentable sq ft
Increase in space: 4,934 rentable sq ft
+2 more
5 metrics
Original leased space
8,774 rentable sq ft
Premises under original sublease at 105 West First Street
Expanded leased space
13,708 rentable sq ft
Premises after First Amendment effective June 29, 2026
Increase in space
4,934 rentable sq ft
Difference between amended and original premises
Increase in future lease payments
$924,000
Additional future minimum lease payments over remaining lease term
Effective Date of amendment
June 29, 2026
Date First Amendment to Sublease became effective
Key Terms
Material Definitive Agreement, Sublease Amendment, future minimum lease payments, Emerging growth company
4 terms
Material Definitive Agreement regulatory
"Item 1.01 Entry into a Material Definitive Agreement."
A material definitive agreement is a legally binding contract that creates major, long‑term obligations or rights for a company, such as loans, asset sales, mergers, or supplier deals. Think of it like a mortgage or lease for a business: it can change future cash flow, risk and control, so investors watch these agreements closely because they can materially affect a company’s value, financial health and stock price.
Sublease Amendment financial
"entered into a First Amendment to the Sublease (the “Sublease Amendment”)"
future minimum lease payments financial
"the Company’s future minimum lease payments will increase by approximately $924,000"
Emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
What did Avalyn Pharma Inc. (AVLN) change in its Boston lease?
Avalyn Pharma amended its sublease for office space in Boston, expanding the leased premises and increasing future minimum lease payments. The change reflects a larger footprint at 105 West First Street under its agreement with CRISPR Therapeutics.
How much additional space did Avalyn Pharma (AVLN) lease in Boston?
Avalyn Pharma expanded its leased premises from about 8,774 to 13,708 rentable square feet, an increase of roughly 4,934 square feet. This larger space remains within the same building at 105 West First Street in Boston, Massachusetts.
How will Avalyn Pharma’s (AVLN) lease amendment affect future payments?
Under the sublease amendment, Avalyn Pharma’s future minimum lease payments will increase by approximately $924,000 over the remaining lease term. This higher commitment corresponds to the expanded rentable square footage in the Boston premises.
Who is Avalyn Pharma’s sublandlord under the amended sublease?
Avalyn Pharma’s sublandlord is CRISPR Therapeutics, Inc. The First Amendment to the Sublease Agreement between Avalyn as subtenant and CRISPR Therapeutics as sublandlord governs the expanded space and increased lease payment obligations.
When did Avalyn Pharma’s amended sublease become effective?
The First Amendment to Avalyn Pharma’s sublease became effective on June 29, 2026. From this effective date, the rentable square footage increased and the revised future minimum lease payment schedule applies for the remaining lease term.